BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver
First Generic Due In 2022; How Will Bristol Fill $12.1bn Gap?
The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.
